Filing Flows

Filing Flows › Eton Pharmaceuticals (ETON) › Who owns the stock

Who owns Eton Pharmaceuticals (ETON) stock

159 funds reported Eton Pharmaceuticals (ETON) shares in their latest 13F filings, worth $774M in all. The largest holder is Opaleye Management ($104M). Last quarter 103 funds added to their stakes and 35 cut them.

Largest holders of ETON (13F)Largest holders of ETON (13F)Opaleye Management$104MNantahala Capital Management, LLC$85.1MEcoR1 Capital, LLC$78.6MBlackRock$68.6MVanguard Capital Management LLC$35.4MMorgan Stanley$27.8MState Street$25.4MGeode Capital Management, LLC$23.6MVanguard Group$22.8MOberweis Asset Management$18.2M

Largest holders (13F)

FundSharesValueChangeQuarter
Opaleye Management2,860,000$104Munchanged2026-06-30
Nantahala Capital Management, LLC2,351,902$85.1Mincrease2026-06-30
EcoR1 Capital, LLC2,171,938$78.6Munchanged2026-06-30
BlackRock1,895,833$68.6Mincrease2026-06-30
Vanguard Capital Management LLC976,570$35.4Mdecrease2026-06-30
Morgan Stanley767,972$27.8Mincrease2026-06-30
State Street701,786$25.4Mincrease2026-06-30
Geode Capital Management, LLC652,303$23.6Mincrease2026-06-30
Vanguard Group1,348,668$22.8Mincrease2025-12-31
Oberweis Asset Management501,600$18.2Mincrease2026-06-30
National Philanthropic Trust492,112$17.8Munchanged2026-06-30
Westside Investment Management431,160$15.6Mdecrease2026-06-30
Pillsbury Lake Capital LLC387,157$14.0Mincrease2026-06-30
Nuveen, LLC375,707$13.6Mincrease2026-06-30
BNP Paribas Financial Markets322,466$11.7Mincrease2026-06-30

Eton Pharmaceuticals' latest quarter

Eton Pharmaceuticals, Q3 2026: revenue $57.9M (+158% year over year), operating margin 39.7%, net earnings $35.2M, operating cash flow $35.2M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most ETON stock?

By the latest 13F filings: Opaleye Management ($104M); Nantahala Capital Management, LLC ($85.1M); EcoR1 Capital, LLC ($78.6M); BlackRock ($68.6M); Vanguard Capital Management LLC ($35.4M).

What is the short interest in ETON?

1,943,339 shares were sold short at the 2026-10-15 settlement, 5.96% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.